Hypothesis: Is a failure to prevent bacteriolysis and the synergy among microbial and host-derived pro-inflammatory agonists the main contributory factors to the pathogenesis of post-infectious sequelae?

Inflammation

Volumn 25, Issue 1, 2001, Pages 1-6

  Ginsburg, I ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AUTACOID; CANNABINOID; CYTOKINE; DEXTRAN SULFATE; DEXTRO AMINO ACID; ENDOTOXIN ANTIBODY; EVANS BLUE; GLUCAN; HEPARIN; HYPERIMMUNE GLOBULIN; INTERLEUKIN 10; INTERLEUKIN 12; NITRIC OXIDE SYNTHASE INHIBITOR; PENTOXIFYLLINE; PLANT EXTRACT; POLYANETHOLESULFONIC ACID; POLYANION; POLYCATION; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SURAMIN;

ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIOLYSIS; CELL DESTRUCTION; CYTOKINE PRODUCTION; CYTOPATHOGENIC EFFECT; EARLY DIAGNOSIS; HEMODIALYSIS; HUMAN; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFLAMMATION; MOLECULAR INTERACTION; NEUTROPHIL; PATHOGENESIS; SEPSIS; SEPTIC SHOCK; TISSUE INJURY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTEREMIA; BACTERIOLYSIS; CELL WALL; CRITICAL CARE; CULTURE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOTOXINS; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MODELS, BIOLOGICAL; PHAGOCYTES; PHAGOCYTOSIS; SEPSIS;

BACTERIA (MICROORGANISMS);

EID: 0035100539     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007024809661     Document Type: Article

References (45)

1. Issues in the adjunct therapy of severe sepsis
2. Sepsis research: We must change course
3. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS) multiple organ failure (MOF): Are we winning the battle?
4. Antiendotoxin strategies for the prevention and treatment of septic shock: New approaches and future directions
5. Immunotherapy of sepsis: Flawed concept or faulty implementation?
6. Therapy of sepsis: Why have we made such little progress?
7. Why immunomodulatory therapies have not worked in sepsis
8. Anti-inflammatory therapies: Application of molecular biology techniques in intensive care medicine
9. Clinical trials in sepsis: Where do we stand?
10. Therapeutic immunomodulatory approaches to the control of systemic inflammatory response syndrome and the prevention of sepsis
11. The inflammatory basis of trauma/shock-associated multiple organ failure
12. Treating patients with severe sepsis
13. Intensive Care Medicine
14. Cell damage in inflammatory and infectious sites might involve a coordinated "cross-talk" among oxidants, microbial hemolysins and amphiphiles, cationic proteins phospholipases, fatty acids, proteinases and cytokines
15. Can we learn from the pathogenetic strategies of group A hemolytic streptococci how tissues are destroyed and organs fail in post-infectious and inflammatory sequelae?
16. Multidrug strategies are necessary to inhibit the synergistic mechanisms causing tissue damage and organ failure in postinfectious sequelae
17. Can hemolytic streptococci be considered forefathers of modern phagocytes? Both cell types freely migrate in tissues and destroy host cells by a "synergistic cross-talk" among their secreted agonists
18. Mechanisms of cell and tissue injury induced by group A streptococci; Relation to post-streptococcal sequelae
19. Reduced virulence of group A streptococcal Tn916 mutant that does not produce streptolysin S
20. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci
21. Inactivation of streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotypes M3 and M49 strains
22. Direct effect of neutrophil oxidants and elastase-induced extra cellular matrix proteolysis
23. Xanthine oxidase-derived toxic oxygen metabolites contribute to lung injury from neutrophil elastase
24. The toxins of group A streptococci, the flesh eating bacteria
25. Cationic proteins of polymorphonuclear leukocyte lysosomes. II. Composition, properties and mechanisms of antibacterial action
26. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense
27. Cationic polyelectrolytes: A new look at their possible roles as opsonins, as stimulators of the respiratory burst in leukocytes, in bacteriolysis, and as modulators of immune-complex diseases
28. I: The biochemistry of bacteriolysis: Paradoxes, facts and myths
29. The significance of endotoxin release in experimental and clinical sepsis, in surgical patients: Evidence for antibiotic-induced endotoxin release?
30. Antibiotic-induced release of bacterial cell-wall components in the pathogenesis of sepsis and septic shock: A review
31. Inhibition of cell wall turnover and autolysis by vancomycin in a high vancomycin-resistant mutant Staphylococcus aureus
32. Clindamycin suppresses endotoxin release by ceftazimine-treated Escherichia coli O55: B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta
33. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: Correlation with inhibition of cytokine production
34. Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either binding of LPS to LBP or the presentation of LPS/LBP complex to CD14
35. LPS-binding protein protect mice from sepstic shock caused by LPS or Gram-negative bacteria
36. Interleukin-10: The ambiguity in sepsis continues
37. Multiple role of IL- 12 in a model of acute septic peritonitis
38. Blocking chemokine receptors
39. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome
40. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis
41. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
42. Tyrfostin AG556 improves survival and reduces multiorgan failure in canine Eschericia coli peritonitis
43. XXXX. Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by a non psychotropic cannabinoid
44. Inhibition of tumor necrosis factor-release in rats experimental endotoxemia by treatment with the 21-aminosteroid U-74389G
45. PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids